Samsung Electronics Co., Ltd.

Other

Driscoll's, Inc.

Millennium Pharmaceuticals Limited

Alexion Pharmaceuticals, Inc.

Membrane Technology and Research, Inc

Vmware, Inc.

Northrop Grumman Systems Corporation

Headwater Partners I LLC

Takeda Gmbh

Millenium Pharmaceuticals, Inc.

Phuong Nguyen

Anugeetha Kunjithapatham

Priyang Rathod

Alan Messer

Mithun Sheshagiri

Simon J Gibbs

Michael D Ferguson

Raymond D Skwierczynski

Nobel T Truong

Michael J Kaufman

Quentin J McCubbin

Eric L Elliott

Vaithianathan Palaniappan

Csanad M Varga

Debra L Mazaik

Abu J Ferdous

Peter Zawaneh

Doreen Cheng

Sonja A Komar-Lay

Philip J Stewart

Ingo Pinnau

Kaaeid A Lokhandwala

Jason W Brown

Kevin Coons

Irving H Fox

Catherine Scholz

Maria Rosario

Sonja A Komar

Peter N Zawaneh

Quentin J Mccubbin

Helen Jenkins

Willow Diluzio

Gregory G Raleigh

James Francis Lavine

Jeffrey Green

Chunbo Zhang

Willow Ruth Diluzio

Xianglin Zeng

Lora G Toy

Scott Segelke

Gregory Allan Sacha

Rick R Giles

Marc L Jacobs

Bottyán Németh

Maria Cruz Ayuso Hernandez

Thang Van Tran

Alberto Algarra

Maria L Tenorio

Abdelali El Tahiri

Juan Wang

Sonja A Komar Lay

Pryiang Rathod

A new and distinct variety of strawberry plant named 'DrisStrawOneHundredNine', particularly selected for its sweet flavor, overall fruit quality, long trusses, and open plant canopy, is disclosed.

Strawberry plant named 'DrisStrawOneHundredNine'

A new and distinct variety of strawberry plant named 'DrisStrawOneHundredSix', particularly selected for its yield potential, uniformity of fruit shape and size, stability of production, fruit flavor, and shelf life, is disclosed.

Strawberry plant named 'DrisStrawOneHundredSix'

A new and distinct variety of strawberry plant named 'DrisStrawOneHundredFive', particularly selected for its fruit flavor, large berry size, early production, fruit quality, and open canopy for faster harvesting, is disclosed.

Strawberry plant named 'DrisStrawOneHundredFive'

The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, and a stabilizer, wherein the formulation does not collapse during lyophilization.

Lyophilized formulations for factor XA antidote

A new and distinct variety of strawberry plant named 'DrisStrawOneHundredTwo', particularly selected for its yield potential, plant habit, and timing of fruit production, is disclosed.

Strawberry plant named 'DrisStrawOneHundredTwo'

A new and distinct variety of strawberry plant named 'DrisStrawNinetyNine', particularly selected for its good fruit quality and flavor, large berry size, early production, and open canopy for ease of harvest, is disclosed.

Strawberry plant named 'DrisStrawNinetyNine'

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Boronate ester compounds and pharmaceutical compositions thereof

A new and distinct variety of strawberry plant named 'DrisStrawNinetyFour', particularly selected for its large berry size, high vigor, long trusses, and flavor of the fruit, is disclosed.

Strawberry plant named 'DrisStrawNinetyFour'

A new and distinct variety of strawberry plant named 'DrisStrawNinetyFive', particularly selected for its large berry size, fruit firmness, open canopy, and long trusses, is disclosed.

Strawberry plant named 'DrisStrawNinetyFive'

A new and distinct variety of strawberry plant named 'DrisStrawNinetyTwo', particularly selected for its fruit flavor, open plant canopy, and long fruit trusses, is disclosed.

Strawberry plant named 'DrisStrawNinetyTwo'

The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least 20 mg/ml, a tonicity modifier, a buffer and one or more of surfactants, amino acids, antioxidants and/or chelators, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders.

Liquid formulation comprising GM-CSF neutralizing compound

A new and distinct variety of strawberry plant named 'DrisStrawEightyFive', particularly selected for its compact plant habit, good fruit quality and flavor, and early yields, is disclosed.

Strawberry plant named 'DrisStrawEightyFive'

The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.

Lyophilized formulations for factor Xa antidote

Growing community of inventors

San Jose, CA, United States of America

Phuong Nguyen